enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 72,700 shares, a growth of 472.4% from the March 31st total of 12,700 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 51,000 shares, the days-to-cover ratio is presently 1.4 days.
Insider Buying and Selling
In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Vivo Capital LLC bought a new stake in enGene during the 4th quarter valued at approximately $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter valued at approximately $10,441,000. BVF Inc. IL bought a new stake in enGene during the 4th quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new stake in enGene during the 4th quarter valued at approximately $80,097,000. Institutional investors own 64.16% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on ENGN
enGene Price Performance
Shares of NASDAQ:ENGN traded up $0.78 during midday trading on Friday, reaching $15.50. 113,417 shares of the company’s stock traded hands, compared to its average volume of 36,859. enGene has a one year low of $6.69 and a one year high of $43.00. The stock’s 50 day moving average price is $16.20.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 4/22 – 4/26
- The How and Why of Investing in Biotech Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- What are earnings reports?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.